

IN THE CLAIMS

Please amend claims 8, 10, 12, and 19-23, and add claims 43-55 as follows:

1-7. (withdrawn)

8. (currently amended) A polypeptide produced by the process of claim 7 a process comprising growing a culture of a host cell in suitable culture medium and isolating the polypeptide from culture, wherein the host cell comprises a nucleic acid molecule comprising a nucleic acid sequence selected from:

a) a nucleotide sequence as set forth in Figure 1A (SEQ ID NO: 1);

b) a nucleotide sequence encoding a polypeptide from residues 1-200 or from residues 21-200 as set forth in Figure 1A (SEQ ID NO: 2);

c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to a polypeptide as set forth in Figure 1A (SEQ ID NO: 2), wherein the polypeptide has at least one activity characteristic of CRP1;

d) a nucleotide sequence complementary to any of (a), (b), or (c);

e) a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide fragment has at least one activity characteristic of CRP1;

f) a nucleotide sequence comprising a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 1A (SEQ ID NO: 1), wherein the polypeptide has at least one activity characteristic of CRP1;

g) a nucleotide sequence that hybridizes over its entire length under high stringency conditions to any of (a)-(f);

h) a nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11);

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

i) a nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO. 7) from residues 1-322 or from residues 47-322, or as set forth in Figure 3A (SEQ ID NO: 12) from residues 1-288 or from residue 19-288, 20-288, 21-288, 22-288, 24-288, or 28-288;

j) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12), wherein the polypeptide has at least one activity characteristic of B7RP1;

k) a nucleotide sequence complementary to any of (h), (i), or (j);

l) a nucleotide sequence of (i) or (j) encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide fragment has at least one activity characteristic of B7RP1;

m) a nucleotide sequence comprising a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11), wherein the polypeptide has at least one activity characteristic of B7RP1; and

n) a nucleotide sequence that hybridizes over its entire length under high stringency conditions to any of (h)-(m);
wherein the nucleic acid molecule is operably linked to an expression control sequence.

9. (withdrawn)

10. (currently amended) A polypeptide encoded by ~~the~~ a nucleic acid molecule ~~of claim 2~~ selected from:

a) a nucleotide sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11);

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

b) a nucleotide sequence encoding the polypeptide as set forth in Figure 2A (SEQ ID NO. 7) from residues 1-322 or from residues 47-322;

c) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11), wherein the isolated polypeptide has at least one activity characteristic of B7RP1;

d) a nucleotide sequence complementary to any of (a), (b), or (c);

e) a nucleotide sequence of (b) or (c) encoding a polypeptide fragment of at least about 50 amino acid residues, wherein the polypeptide fragment has at least one activity characteristic of B7RP1;

f) a nucleotide sequence of comprising a fragment of at least about 75 nucleotides of the sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ IS NO: 11), wherein the polypeptide fragment has at least one activity characteristic of B7RP1; and

g) a nucleotide sequence that hybridizes over its entire length under high stringency conditions to any of (a)-(f).

11. (withdrawn)

12. (currently amended) An isolated polypeptide comprising ~~the~~an amino acid sequence selected from the group consisting of:

a) ~~the~~an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) ~~or Figure 12A (SEQ ID NO: 17);~~

b) ~~the~~a mature amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) comprising a mature amino terminus at residues 47, or Figure 3A (SEQ ID NO: 12) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28, or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Figure 12A (SEQ ID NO: 17) comprising a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28; and

c) a fragment of ~~the~~ an amino acid sequence set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) ~~or Figure 12A (SEQ ID NO: 17)~~ comprising at least about 25, 50, 75, 100, ~~or greater than 100~~ amino acid residues, wherein the fragment has at least one activity characteristic of B7RP1;

d) ~~an ortholog of (a), (b) or (c); and~~

e) ~~an allelic variant or alternative splice variant of (a), (b), (c) or (d).~~

13-18 (withdrawn)

19. (currently amended) A composition comprising ~~the~~ a polypeptide of ~~Claims 9, 10, 11, or 12~~ and a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer or anti-oxidant, wherein the polypeptide is the isolated polypeptide of claims 8, 10, or 12.

20. (currently amended) A polypeptide comprising a derivative of ~~the~~ a polypeptide of claims ~~9~~, 10, 11, or 12.

21. (original) The polypeptide of Claim 20 which is covalently modified with a water-soluble polymer.

22. (currently amended) A fusion polypeptide comprising ~~the~~ a polypeptide of Claims ~~9~~, 10, 11, or 12 fused to a heterologous amino acid sequence.

23. (original) The fusion polypeptide of claim 22, wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof.

24-42 (withdrawn)

43. (new) The isolated polypeptide of claim 12 comprising an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

44. (new) The isolated polypeptide of claim 12 consisting of an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12).

45. (new) The isolated polypeptide of claim 12 comprising a fragment of an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 7) or Figure 3A (SEQ ID NO: 12) comprising at least about 50 amino acid residues, wherein the fragment has at least one activity characteristic of B7RP1.

46. (new) An isolated polypeptide comprising an amino acid sequence that is at least about 70 percent identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 12), wherein the isolated polypeptide has at least one activity characteristic of B7RP1.

47. (new) An isolated polypeptide comprising a fragment of at least about 50 amino acid residues; wherein the fragment comprises an amino acid sequence that is at least about 70 percent identical to an amino acid sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID: NO 12); and wherein the fragment has at least one activity characteristic of B7RP1.

48. (new) An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO. 17) with a mature amino terminus at any of residues 19, 20, 21, 22, 24, or 28, wherein the isolated polypeptide has at least one activity characteristic of B7RP1.

49. (new) An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO. 17) comprising a carboxy terminus at about residue 302, wherein the polypeptide has at least one activity characteristic of B7RP1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

50. (new) An isolated polypeptide comprising an amino acid sequence as set forth in Figure 12A (SEQ ID NO: 17).

51. (new) An isolated polypeptide consisting of an amino acid sequence as set forth in Figure 12A (SEQ ID NO: 17).

52. (new) The isolated polypeptide of claim 10 encoded by a nucleic acid molecule comprising a sequence as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11).

53. (new) The isolated polypeptide of claim 10 encoded by a nucleic acid molecule which is capable of hybridizing over its entire length to a nucleic acid molecule that is complementary to a nucleic acid molecule as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11) under high stringency conditions.

54. (new) The isolated polypeptide of claim 10, wherein the isolated polypeptide is encoded by a nucleic acid molecule comprising a sequence that is at least about 95% identical to a nucleic acid as set forth in Figure 2A (SEQ ID NO: 6) or Figure 3A (SEQ ID NO: 11) and wherein the isolated polypeptide has at least one activity characteristic of B7RP1.

55. (new) An isolated polypeptide encoded by a nucleic acid molecule consisting of a nucleotide sequence as set forth in Figure 12A (SEQ ID NO: 16).

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com